Klaus Strebel

List of Publications by Year
in descending order

66 papers	5,613 citations	101543 36 h-index	102487 66 g-index
66 all docs	66 docs citations	66 times ranked	3677 citing authors

#	Article	IF	Citations
1	Simian Immunodeficiency Virus SIVgsn-99CM71 Vpu Employs Different Amino Acids To Antagonize Human and Greater Spot-Nosed Monkey BST-2. Journal of Virology, 2022, 96, JVI0152721.	3.4	1
2	The Myeloid-Specific Transcription Factor PU.1 Upregulates Mannose Receptor Expression but Represses Basal Activity of the HIV-LTR Promoter. Journal of Virology, 2022, 96, .	3.4	4
3	APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner. Journal of Virology, 2021, 95, e0117021.	3.4	3
4	Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs. Journal of Virology, 2020, 94, .	3.4	3
5	Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta. Journal of Virology, 2020, 94, .	3.4	5
6	Antiviral Activity and Adaptive Evolution of Avian Tetherins. Journal of Virology, 2020, 94, .	3.4	4
7	Vpr and Its Cellular Interaction Partners: R We There Yet?. Cells, 2019, 8, 1310.	4.1	31
8	Cytokine Effects on the Entry of Filovirus Envelope Pseudotyped Virus-Like Particles into Primary Human Macrophages. Viruses, 2019, 11, 889.	3.3	3
9	Mannose Receptor 1 Restricts HIV Particle Release from Infected Macrophages. Cell Reports, 2018, 22, 786-795.	6.4	25
10	Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages. PLoS Pathogens, 2018, 14, e1007372.	4.7	19
11	Long-term passage of Vif-null HIV-1 in CD4 + T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance. Virology, 2017, 504, 1-11.	2.4	7
12	Pyviko: an automated Python tool to design gene knockouts in complex viruses with overlapping genes. BMC Microbiology, 2017, 17, 12.	3.3	7
13	Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates. Journal of Virology, 2016, 90, 11062-11074.	3.4	12
14	Low dNTP levels are necessary but may not be sufficient for lentiviral restriction by SAMHD1. Virology, 2016, 488, 271-277.	2.4	55
15	Positioning of Cysteine Residues within the N-terminal Portion of the BST-2/Tetherin Ectodomain Is Important for Functional Dimerization of BST-2. Journal of Biological Chemistry, 2015, 290, 3740-3751.	3.4	9
16	The Expression of Functional Vpx during Pathogenic SIVmac Infections of Rhesus Macaques Suppresses SAMHD1 in CD4+ Memory T Cells. PLoS Pathogens, 2015, 11, e1004928.	4.7	21
17	Fibrocytes Differ from Macrophages but Can Be Infected with HIV-1. Journal of Immunology, 2015, 195, 4341-4350.	0.8	12
18	Activation of HIV-1 from Latent Infection via Synergy of RUNX1 Inhibitor Ro5-3335 and SAHA. PLoS Pathogens, 2014, 10, e1003997.	4.7	57

#	Article	IF	Citations
19	HIV-1 Vpu â€” an ion channel in search of a job. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1074-1081.	2.6	40
20	CBFÎ² Enhances <i>De Novo</i> Protein Biosynthesis of Its Binding Partners HIV-1 Vif and RUNX1 and Potentiates the Vif-Induced Degradation of APOBEC3G. Journal of Virology, 2014, 88, 4839-4852.	3.4	23
21	HIV accessory proteins versus host restriction factors. Current Opinion in Virology, 2013, 3, 692-699.	5.4	111
22	Restriction of Virus Infection but Not Catalytic dNTPase Activity Is Regulated by Phosphorylation of SAMHD1. Journal of Virology, 2013, 87, 11516-11524.	3.4	139
23	The Size and Conservation of a Coiled-coil Structure in the Ectodomain of Human BST-2/Tetherin Is Dispensable for Inhibition of HIV-1 Virion Release. Journal of Biological Chemistry, 2012, 287, 44278-44288.	3.4	19
24	Identification and characterization of naturally occurring splice variants of SAMHD1. Retrovirology, 2012, 9, 86.	2.0	31
25	The Interferon-Inducible Host Factor Bone Marrow Stromal Antigen 2/Tetherin Restricts Virion Release, but Is It Actually a Viral Restriction Factor?. Journal of Interferon and Cytokine Research, 2011, 31, 137-144.	1.2	31
26	Identification of Residues in the BST-2 TM Domain Important for Antagonism by HIV-1 Vpu Using a Gain-of-Function Approach. Frontiers in Microbiology, 2011, 2, 35.	3.5	15
27	Identification of Amino Acids in the Human Tetherin Transmembrane Domain Responsible for HIV-1 Vpu Interaction and Susceptibility. Journal of Virology, 2011, 85, 932-945.	3.4	72
28	Antibody-Mediated Enhancement of HIV-1 and HIV-2 Production from BST-2/Tetherin-Positive Cells. Journal of Virology, 2011, 85, 11981-11994.	3.4	8
29	Some Human Immunodeficiency Virus Type 1 Vpu Proteins Are Able To Antagonize Macaque BST-2 In Vitro and In Vivo: Vpu-Negative Simian-Human Immunodeficiency Viruses Are Attenuated In Vivo. Journal of Virology, 2011, 85, 9708-9715.	3.4	23
30	C-terminal Hydrophobic Region in Human Bone Marrow Stromal Cell Antigen 2 (BST-2)/Tetherin Protein Functions as Second Transmembrane Motif. Journal of Biological Chemistry, 2011, 286, 39967-39981.	3.4	34
31	Differential Effects of Human Immunodeficiency Virus Type 1 Vpu on the Stability of BST-2/Tetherin. Journal of Virology, 2011, 85, 2611-2619.	3.4	46
32	Identification of Dominant Negative Human Immunodeficiency Virus Type 1 Vif Mutants That Interfere with the Functional Inactivation of APOBEC3G by Virus-Encoded Vif. Journal of Virology, 2010, 84, 5201-5211.	3.4	30
33	Stably Expressed APOBEC3F Has Negligible Antiviral Activity. Journal of Virology, 2010, 84, 11067-11075.	3.4	45
34	CD317/Tetherin Is Enriched in the HIV-1 Envelope and Downregulated from the Plasma Membrane upon Virus Infection. Journal of Virology, 2010, 84, 4646-4658.	3.4	94
35	Multilayered Mechanism of CD4 Downregulation by HIV-1 Vpu Involving Distinct ER Retention and ERAD Targeting Steps. PLoS Pathogens, 2010, 6, e1000869.	4.7	145
36	HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Molecular Aspects of Medicine, 2010, 31, 407-417.	6.4	38

#	Article	IF	Citations
37	Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2868-2873.	7.1	204
38	Differential Sensitivity of â€œOldâ€•versus â€œNewâ€•APOBEC3G to Human Immunodeficiency Virus Type 1 Vif. Journal of Virology, 2009, 83, 1156-1160.	3.4	15
39	Human cellular restriction factors that target HIV-1 replication. BMC Medicine, 2009, 7, 48.	5.5	120
40	The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology, 2009, 6, 80.	2.0	139
41	APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages. Virology, 2008, 379, 266-274.	2.4	11
42	HIV-1 Vif, APOBEC, and Intrinsic Immunity. Retrovirology, 2008, 5, 51.	2.0	290
43	APOBEC3G encapsidation into HIV-1 virions: which RNA is it?. Retrovirology, 2008, 5, 55.	2.0	46
44	HIV Accessory Genes Vif and Vpu. Advances in Pharmacology, 2007, 55, 199-232.	2.0	21
45	Human Immunodeficiency Virus Type 1 Vif Inhibits Packaging and Antiviral Activity of a Degradation-Resistant APOBEC3G Variant. Journal of Virology, 2007, 81, 8236-8246.	3.4	83
46	Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1. Journal of Virology, 2007, 81, 13346-13353.	3.4	137
47	Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology, 2007, 4, 48.	2.0	70
48	Monomeric APOBEC3G Is Catalytically Active and Has Antiviral Activity. Journal of Virology, 2006, 80, 4673-4682.	3.4	76
49	Viral RNA Is Required for the Association of APOBEC3G with Human Immunodeficiency Virus Type 1 Nucleoprotein Complexes. Journal of Virology, 2005, 79, 5870-5874.	3.4	170
50	APOBEC3G & HTLV-1: inhibition without deamination. Retrovirology, 2005, 2, 37.	2.0	32
51	Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology, 2004, 319, 163-175.	2.4	149
52	Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology, 2004, 1, 27.	2.0	89
53	HIV-1 Vpu. Molecular Cell, 2004, 14, 150-152.	9.7	14
54	Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology, 2003, 309, 85-98.	2.4	39

#	Article	IF	Citations
55	The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes and Infection, 2003, 5, 1029-1039.	1.9	104
56	Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15154-15159.	7.1	153
57	The Human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity. Journal of Virology, 2003, 77, 11398-11407.	3.4	289
58	Virusâ€“host interactions. Aids, 2003, 17, S25-S34.	2.2	50
59	The Human Immunodeficiency Virus Type 1 Accessory Protein Vpu Induces Apoptosis by Suppressing the Nuclear Factor ÎºBâ€“dependent Expression of Antiapoptotic Factors. Journal of Experimental Medicine, 2001, 194, 1299-1312.	8.5	139
60	The Human Immunodeficiency Virus Type 1 Vpu Protein Inhibits NF-ÎºB Activation by Interfering with Î²TrCP-mediated Degradation of IÎºB. Journal of Biological Chemistry, 2001, 276, 15920-15928.	3.4	164
61	Regulation of Virus Release by the Macrophage-Tropic Human Immunodeficiency Virus Type 1 AD8 Isolate Is Redundant and Can Be Controlled by either Vpu or Env. Journal of Virology, 1999, 73, 887-896.	3.4	73
62	Chicoric Acid Analogues as HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry, 1999, 42, 1401-1414.	6.4	149
63	A Novel Human WD Protein, h-Î²TrCP, that Interacts with HIV-1 Vpu Connects CD4 to the ER Degradation Pathway through an F-Box Motif. Molecular Cell, 1998, 1, 565-574.	9.7	630
64	Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Letters, 1996, 398, 12-18.	2.8	266
65	The Human Immunodeficiency Virus Type 1 Encoded Vpu Protein is Phosphorylated by Casein Kinase-2 (CK-2) at Positions Ser52 and Ser56 within a Predicted Î±-Helix-Turn-Î±-Helix-Motif. Journal of Molecular Biology, 1994, 236, 16-25.	4.2	164
66	The HIV A (sor) gene product is essential for virus infectivity. Nature, 1987, 328, 728-730.	27.8	505